MP-08.18
Urology(2006)
Abstract
Degarelix is a gonadotropin-releasing hormone (GnRH) blocker with an immediate onset of action that produces fast, profound and sustained suppression of serum testosterone (T) levels, without T surge. International, multicentre, phase II studies were performed to determine the optimal initiation dose (studies 1 and 2) and maintenance dose (study 2) of Degarelix for hormonal therapy of prostate cancer (CaP).
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined